StockData

Biodesix vs MDxHealth

BDSX and MDXH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BDSX and MDXH compare

Biodesix grew revenue faster over the last twelve months (31.2% versus 19.8% for MDxHealth).

Biodesix keeps more of each dollar of sales as profit, with a net margin of −25.7% compared with −31.1% at MDxHealth.

MDxHealth scores higher on the StockData Score (5 against 4 for Biodesix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBDSXMDXH
Size and price
Market cap$103M–
Share price$9.79$0.140
Change, 1 year17.4%−96.9%
Change, 5 years−92.3%−98.6%
Beta (5Y)0.740.96
Employees334364
StockData Score
Total score45 (better)
Valuation score00
Growth score23 (better)
Performance score11
Health score11
Dividend score00
Valuation
P/S1.0×–
P/B11.9×–
FCF yield−18.5%–
Growth
Revenue growth (TTM)31.2% (better)19.8%
Revenue growth, 5Y average14.2%42.3% (better)
Profitability
Gross margin–64.5%
Operating margin−18.7%−13.4% (better)
Net margin−25.7% (better)−31.1%
FCF margin−18.1%−3.1% (better)
Return on equity−779%–
Return on invested capital−55.4%–
Financial health
Debt / equity5.43–
Interest coverage−2.5×−0.6× (better)
Current ratio2.96 (better)1.08
Altman Z-score−6.25–
Piotroski F-score33
Dividends and buybacks
Buyback yield−31.7%–
Shareholder yield−31.7%–
Ownership
Held by institutions41.4%32.3%
Insider net buying, 12 months$3.0M (better)$991K

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.